Endoxifen – A novel Bipolar Acute Mania management Molecule
- Endoxifen is a direct PKC inhibitor, target for acute mania the existing treatment options including lithium and valproate indirectly inhibit PKC
- Endoxifen has shown better safety profile as compared to divalproex sodium in terms of having lesser adverse events of like nausea, generalized abdominal pain, dyslipidemia and insomnia
- Endoxifen shows similar efficacy at much lower dose (8 mg) and offers unique advantage of hitting a pharmacological target in a more potent manner
- The tablet size of Endoxifen is small (8 mg) and hence offers more convenience for its daily regular intake for patients
- Unlike lithium and valproate there is no need of therapeutic drug monitoring or dose titration
- Potential drug drug interaction are less compared to other treatments